Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis (EASE)

Next Previous
Trial Profile

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis (EASE)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INCB 000262 (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Proof of concept
  • Acronyms EASE
  • Sponsors Escient Pharmaceuticals

Most Recent Events

  • 30 Aug 2024 Status changed from active, no longer recruiting to completed.
  • 13 May 2024 Status changed from recruiting to active, no longer recruiting.
  • 28 Nov 2023 According to an Escient Pharmaceuticals media release, first subject has been dosed in this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top